There are some startling statistics presented in this research article from the American Cancer Society – most notably, that nearly 50% of cancer survivors who were studied had or expected to face significant financial debt due to their cancer and cancer treatment, while, at the same time, almost ALL of those same survivors had insurance. What is wrong with this picture you ask? Plenty.
Archives: News
News stories
Cancer Survivors Can Get Tired of Being Called ‘Strong’
The author hits the nail on the head with this one. This short piece beautifully and concisely describes yet another of the emotional battles that cancer survivors endure.
Four Steps You Can Take To Manage Your Post-Cancer Fears
Here is a brief article on a subject that we know all too well. It seems to be virtually impossible to escape the “post cancer fear” phenomenon, no matter how well you may be feeling. It may be even more difficult for those of us who continue to experience the late effects of treatments. As the wonderful Roseanne Roseannadanna used to say, “It’s always something!” Owning those fears, as it turns out, could be part of turning the corner.
Two Marathon Runners And Hodgkin’s Lymphoma Survivors – Giving Back And Doing Incredible Things
By Matt Ellis and Regina Norfolk – January 2024 marked 25 years that Elena Togashi has been in remission from Hodgkin lymphoma. To mark this incredible milestone, the 45-year-old cancer survivor will run this year’s Boston Marathon with the Dana-Farber Marathon Challenge team.
Continue reading “Two Marathon Runners And Hodgkin’s Lymphoma Survivors – Giving Back And Doing Incredible Things”
You Aren’t Alone: Navigating the Financial Impact of Cancer
The Leukemia and Lymphoma Society offers numerous programs and webinars via their website and “The Bloodline With LLS.” This webinar is a great example of how LLS continues to support survivors of all ages. Monica Bryant, cancer rights attorney and founder of “Triage Cancer” provides spot-on advice as well as several resources on the subject of financial toxicity.
New Combination Chemotherapy For Untreated Hodgkin Lymphoma Feasible In Older Patients
A new first-line chemotherapy regimen of prednisone, vinblastine, doxorubicin, and bendamustine (PVAB) yields a high complete metabolic response (CMR) rate with acceptable toxicity in older patients with classical Hodgkin lymphoma (cHL), according to research published in Blood.
Childhood Cancer Survivors At Greater Risk For Death After Major Cardiovascular Event
This article describes research done by the Childhood Cancer Survivor Study of St. Jude Children’s Research Hospital and CARDIA, which stands for “Coronary Artery Risk Development in Young Adults.” These two organizations combined their data bases to create an in-depth study of the specific risks for childhood cancer survivors. The results are concerning, and they underline the need for early and frequent observation post treatment.
Dana-Farber Adult Survivorship Program
The Adult Survivorship Program team and Lymphoma Division at Dana-Farber Cancer Institute has created an evidence-based Hodgkin Lymphoma online educational resource website for Hodgkin Lymphoma survivors, loved ones, caregivers, and clinicians. We have designed this program to describe the different aspects of survivorship for Hodgkin Lymphoma patients, including cancer risks, care of your heart, healthy living, emotional well-being, family and relationships, and general tips. This website provides specific strategies to manage potential late and long-term effects from chemotherapy and/or radiation for Hodgkin Lymphoma and other related cancers. We formatted it in a way that site visitors are able to go through each module and read through all the content and diverse topics.
The Late Effects Of Childhood Cancer
Hodgkin’s International was honored to be mentioned in this recent article about late effects that appeared in “Cancer Today,” a publication of the American Association for Cancer Research.
Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors Treated With Doxorubicin
The research was presented in October, 2022 at the International Symposium on Hodgkin Lymphoma and earlier, at the ASCO (American Society for Clinical Oncology) Annual Meeting in 2021. A common chemotherapy drug used to treat Hodgkin lymphoma conferred a significantly increased risk of breast cancer among women treated during adolescence and adulthood, a large retrospective study showed.